Olanzapine: Pharmacology, pharmacokinetics and therapeutic drug monitoring;Olanzapin: Pharmakologie, pharmakokinetik und therapeutisches drug monitoring

Fortschritte der Neurologie Psychiatrie

Volumn 69, Issue 11, 2001, Pages 510-517

  Rao, M L ^a   Hiemke, C ^b   Grasmader K ^a   Baumann, P ^c  

^a UNIVERSITY OF BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AGRANULOCYTOSIS; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME INDUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETHALITY; MALE; NEUTROPENIA; OXIDATIVE STRESS; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; PIRENZEPINE; SEROTONIN UPTAKE INHIBITORS; SMOKING; WEIGHT GAIN;

EID: 0035178179     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18381     Document Type: Article

References (50)

1. Olanzapine versus placebo and haloperidol. Acute phase results of the North American doubleblind olanzapine trial
2. The new generation of antipsychotic drugs: How atypical are they?
3. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms
4. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol
5. Receptor pharmacology of neuroleptics: Relation to clinical effects
6. The role of serotonin in antipsychotic drug action
7. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
8. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
9. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
10. Blind, controlled, long-term study of the comparative incidence of treatmentemergent tardive dyskinesia with olanzapine or haloperidol
11. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia
12. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
13. Prolaktinantwort und psychophysiologische Reaktion auf Neuroleptika bei Frauen und Männem
14. Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by HPLC with electrochemical detection
15. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry
16. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection
17. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column switching high performance liquid chromatography
18. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure
19. Pharmacokinetics and drug interactions: Update for new antipsychotics
20. Olanzapine: A serotonin-dopamine-receptor antagonist for antipsychotic therapy
21. Olanzapin. Ein neues Neuroleptikum mit "atypischem" Wirkungsprofil
22. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
23. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication
24. Olanzapine: Pharmacokinetic and pharmacodynamic profile
25. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism
26. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine
27. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 AND CYP3A
28. Drug metabolism and atypical antipsychotics
29. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
30. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia
31. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
32. Weight change and atypical antipsychotic treatment in patients with schizophrenia
33. Zur pathophysiologie der gewichtsregulation im rahmen der therapie mit psychopharmaka
34. Body weight and leptin plasma levels during treatment with antipsychotic drugs
35. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine
36. Antipsychotic-induced weight gain: A comprehensive research synthesis
37. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine
38. Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics
39. Olanzapine concentrations in clinical serum and postmortem blood specimens - When does therapeutic become toxic?
40. Olanzapine associated deaths: A report of five cases
41. Olanzapine concentrations in forensic investigations
42. Thirty-five case studies involving postmortem tissue distribution of olanzapine (Zyprexa)
43. Blutbildveränderungen unter dem neueren atypischen neuroleptikum olanzapin
44. Olanzapine-induced agranulocytosis
45. Olanzapine-induced neutropenia after clozapine-induced neutropenia
46. Two cases of olanzapine-induced reversible neutropenia
47. Genetic determinants of drug induced agranulocytosis: Potential risk of olanzapine?
48. Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia
49. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients
50. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American olanzapine trial